Docetaxel, cisplatin, and fluorouracil combination in neoadjuvant setting in the treatment of locally advanced gastric adenocarcinoma: Phase II NEOTAX study

Ozdemir, Nuriye; Abali, Huseyin; Vural, Murat; YALÇIN, ŞUAYİB; Oksuzoglu, Berna; Civelek, Burak; Oguz, Dilek; Bostanci, Birol; Yalcin, Bulent; Zengin, Nurullah

doi:10.1007/s00280-014-2586-6

Docetaxel, cisplatin, and fluorouracil combination in neoadjuvant setting in the treatment of locally advanced gastric adenocarcinoma: Phase II NEOTAX study

Atıf İçin Kopyala

Ozdemir N., Abali H., Vural M., YALÇIN Ş., Oksuzoglu B., Civelek B., ...Daha Fazla

CANCER CHEMOTHERAPY AND PHARMACOLOGY, cilt.74, sa.6, ss.1139-1147, 2014 (SCI-Expanded)

Yayın Türü: Makale / Tam Makale
Cilt numarası: 74 Sayı: 6
Basım Tarihi: 2014
Doi Numarası: 10.1007/s00280-014-2586-6
Dergi Adı: CANCER CHEMOTHERAPY AND PHARMACOLOGY
Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
Sayfa Sayıları: ss.1139-1147
Hacettepe Üniversitesi Adresli: Evet

Özet

This phase II trial aimed to evaluate the efficacy and safety of docetaxel, cisplatin, and fluorouracil (DCF) combination in neoadjuvant setting in patients with locally advanced gastric adenocarcinoma.